PhRMA defends FDA's OTC office as "important focal point" for OTC policy issues.
This article was originally published in The Tan Sheet
Executive Summary
PhRMA CALLS OFFICE OF OTC DRUGS "IMPORTANT FOCAL POINT" FOR POLICY ISSUES involving nonprescription drugs in a section- by-section analysis of its draft FDA reform legislation that is being circulated on Capitol Hill. The Pharmaceutical Research & Manufacturers Association noted that, since its inception in the early 1990s, the Office of OTC Drug Evaluation "has gradually become an important focal point for policy issues" related to over-the-counter drugs, and "has played a constructive role in the consideration of each proposed switch of a drug from prescription to nonprescription status."